Dur encompasses a drug review against predetermined criteria that results in changes to drug therapy when these criteria are not met. Drug utilization review (dur) since 1993, section 1927 (g) of the act has required each state to develop a dur program targeted, in part, at reducing clinical abuse and misuse of outpatient prescription drugs covered under the state’s medicaid program. A drug utilization review (dur) is a program designed to enhance the safety and effectiveness of prescription drug use These reviews include studies conducted on drugs prior to their commercial release and public use, as well as ongoing studies after they are prescribed to patients. Drug utilization review (dur) assistance is available to assist state medicaid agencies in developing, enhancing, implementing, and evaluating regulations and programs to ensure appropriate drug therapy and streamline fraud, misuse and abuse. A drug utilization review (dur) is a systematic examination of prescription drug use patterns and patient medication histories to ensure the appropriate and safe use of medications.
Drug utilization review (dur) is a process by which healthcare entities can ensure they are properly prescribing, dispensing, and making use of prescription medication. States are required to establish a drug use review board (dur board) that assists the state with dur activities The scope of dur activities must include prospective and retrospective dur, assessment of drug use against predetermined standards, and educational programs.
OPEN
